Novartis AG (NVS)

77.54
0.69 0.90
NYSE : Health Care
Prev Close 76.85
Open 77.35
Day Low/High 77.07 / 77.63
52 Wk Low/High 66.93 / 83.58
Volume 1.80M
Avg Volume 3.36M
Exchange NYSE
Shares Outstanding 2.37B
Market Cap 182.90B
EPS 2.80
P/E Ratio 27.32
Div & Yield 2.75 (3.60%)

Latest News

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Propeller Health Enters Into Collaboration To Connect Breezhalerâ„¢ Devices To The Propeller Platform

Propeller Health Enters Into Collaboration To Connect Breezhalerâ„¢ Devices To The Propeller Platform

Partnership adds another important family of leading respiratory brands and solidifies Propeller's position as the leading digital platform in respiratory medicine

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis is taking another step to move immunotherapy 'off the shelf.'

Mallinckrodt Divests Drug Delivery Unit as Shedding Continues

Mallinckrodt Divests Drug Delivery Unit as Shedding Continues

The pharmaceutical company has signed a deal to sell its intrathecal therapy segment to a Piramal Enterprises subsidiary for up to $203 million.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Dow Sets New Record After Smashing Through 20,000 Milestone

Dow Sets New Record After Smashing Through 20,000 Milestone

It finally did it. The Dow Jones Industrial Average smashed through 20,000 after hemming and hawing over the milestone.

Dow Posts Solid Gains After Crossing the 20,000 Milestone

Dow Posts Solid Gains After Crossing the 20,000 Milestone

After slaying its 20,000 milestone Wednesday morning, the Dow Jones Industrial Average extends gains through the afternoon to make a play for 20,100.

What Next as Dow Breaks Through Historic Milestone?

What Next as Dow Breaks Through Historic Milestone?

The Dow Jones Industrial Average finally pushes past the 20,000 milestone after teetering close to that level weeks earlier.

Positive Earnings Are Setting Up the Dow for Its Push to 20,000

Positive Earnings Are Setting Up the Dow for Its Push to 20,000

A series of positive earnings on Wednesday morning set the Dow Jones Industrial Average up to close in on its 20,000 milestone.

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Reports from DuPont and Alibaba looked promising for the markets on Wednesday.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures rise Wednesday and European stocks book solid gains as corporate earnings in the U.S. drive Wall Street higher.

News Out of Europe: Intesa Confirms Potential Bid for Generali

News Out of Europe: Intesa Confirms Potential Bid for Generali

News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.

European Stocks Book Solid Gains as Earnings, Deal Speculation Boost Sentiment

European Stocks Book Solid Gains as Earnings, Deal Speculation Boost Sentiment

European stocks notched solid gains Wednesday as global equity investors build on a strong U.S. corporate earnings season, European deal speculation and encouraging economic data from Japan.

Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff

Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff

Novartis missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Regulators say company squelched competing drug for infant seizures.

Mallinkrodt Shares Tank Despite $100 Million FTC Deal

Mallinkrodt Shares Tank Despite $100 Million FTC Deal

Drugmaker faced antitrust charges over 2013 Synacthen purchase.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.